Comparison of clinical efficacy between decitabine combined with half the amount of CAG regimen with CAG regimen alone in patients with inermediate to high-risk myelodysplastic syndrome
Objective: To investigate the efficacy and safety of decitabine combined with half the amount of CAG and CAG regimen alone. Methods: Comparison the effectiveness, overall survival and incidence of adverse reactions of 42 cases of MDS used decitabine combined with half the amount of CAG regimen (deci...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
EDP Sciences
2017-01-01
|
| Series: | BIO Web of Conferences |
| Online Access: | http://dx.doi.org/10.1051/bioconf/20170801024 |
| _version_ | 1818661912898961408 |
|---|---|
| author | Fan Zhenwei Wang Xuan Zhao Chunshan Wang Wei Yu Tingting |
| author_facet | Fan Zhenwei Wang Xuan Zhao Chunshan Wang Wei Yu Tingting |
| author_sort | Fan Zhenwei |
| collection | DOAJ |
| description | Objective: To investigate the efficacy and safety of decitabine combined with half the amount of CAG and CAG regimen alone. Methods: Comparison the effectiveness, overall survival and incidence of adverse reactions of 42 cases of MDS used decitabine combined with half the amount of CAG regimen (decitabine 20mg/m2, once a day, d1-3, Accra neomycin 7mg/m2,intravenous injection, once a day, d4-7, cytarabine 10mg/m2, every 12 hours, d4-10, granulocyte colony stimulating factor 300μg, once a day, d4-10, white blood cell count>20×109/L when deactivated for four courses) and 48 patients in MDS were treated with chemotherapy alone CAG (Accra neomycin 14mg/m2,once a day, d1-3, cytarabine 10mg/m2, every 12 hours, d1-14, granulocyte colony stimulating factor 300μg, once a day, d1-14, white blood cell count>20×109/L when deactivated). Results: Compared with pure CAG, clinical efficacy of decitabine combined with half the amount of CAG regimen is better, the treatment does not increase the risk. |
| first_indexed | 2024-12-17T04:52:36Z |
| format | Article |
| id | doaj.art-2e622d3bc0c74ecf8c2be4c360c3b0bd |
| institution | Directory Open Access Journal |
| issn | 2117-4458 |
| language | English |
| last_indexed | 2024-12-17T04:52:36Z |
| publishDate | 2017-01-01 |
| publisher | EDP Sciences |
| record_format | Article |
| series | BIO Web of Conferences |
| spelling | doaj.art-2e622d3bc0c74ecf8c2be4c360c3b0bd2022-12-21T22:02:51ZengEDP SciencesBIO Web of Conferences2117-44582017-01-0180102410.1051/bioconf/20170801024bioconf_icmsb2017_01024Comparison of clinical efficacy between decitabine combined with half the amount of CAG regimen with CAG regimen alone in patients with inermediate to high-risk myelodysplastic syndromeFan Zhenwei0Wang Xuan1Zhao Chunshan2Wang Wei3Yu Tingting4College Nursing of Beihua UniversityHematology of Affiliated Hospital of Beihua UniversityCollege Nursing of Beihua UniversityHematology of Affiliated Hospital of Beihua UniversityHematology of Affiliated Hospital of Beihua UniversityObjective: To investigate the efficacy and safety of decitabine combined with half the amount of CAG and CAG regimen alone. Methods: Comparison the effectiveness, overall survival and incidence of adverse reactions of 42 cases of MDS used decitabine combined with half the amount of CAG regimen (decitabine 20mg/m2, once a day, d1-3, Accra neomycin 7mg/m2,intravenous injection, once a day, d4-7, cytarabine 10mg/m2, every 12 hours, d4-10, granulocyte colony stimulating factor 300μg, once a day, d4-10, white blood cell count>20×109/L when deactivated for four courses) and 48 patients in MDS were treated with chemotherapy alone CAG (Accra neomycin 14mg/m2,once a day, d1-3, cytarabine 10mg/m2, every 12 hours, d1-14, granulocyte colony stimulating factor 300μg, once a day, d1-14, white blood cell count>20×109/L when deactivated). Results: Compared with pure CAG, clinical efficacy of decitabine combined with half the amount of CAG regimen is better, the treatment does not increase the risk.http://dx.doi.org/10.1051/bioconf/20170801024 |
| spellingShingle | Fan Zhenwei Wang Xuan Zhao Chunshan Wang Wei Yu Tingting Comparison of clinical efficacy between decitabine combined with half the amount of CAG regimen with CAG regimen alone in patients with inermediate to high-risk myelodysplastic syndrome BIO Web of Conferences |
| title | Comparison of clinical efficacy between decitabine combined with half the amount of CAG regimen with CAG regimen alone in patients with inermediate to high-risk myelodysplastic syndrome |
| title_full | Comparison of clinical efficacy between decitabine combined with half the amount of CAG regimen with CAG regimen alone in patients with inermediate to high-risk myelodysplastic syndrome |
| title_fullStr | Comparison of clinical efficacy between decitabine combined with half the amount of CAG regimen with CAG regimen alone in patients with inermediate to high-risk myelodysplastic syndrome |
| title_full_unstemmed | Comparison of clinical efficacy between decitabine combined with half the amount of CAG regimen with CAG regimen alone in patients with inermediate to high-risk myelodysplastic syndrome |
| title_short | Comparison of clinical efficacy between decitabine combined with half the amount of CAG regimen with CAG regimen alone in patients with inermediate to high-risk myelodysplastic syndrome |
| title_sort | comparison of clinical efficacy between decitabine combined with half the amount of cag regimen with cag regimen alone in patients with inermediate to high risk myelodysplastic syndrome |
| url | http://dx.doi.org/10.1051/bioconf/20170801024 |
| work_keys_str_mv | AT fanzhenwei comparisonofclinicalefficacybetweendecitabinecombinedwithhalftheamountofcagregimenwithcagregimenaloneinpatientswithinermediatetohighriskmyelodysplasticsyndrome AT wangxuan comparisonofclinicalefficacybetweendecitabinecombinedwithhalftheamountofcagregimenwithcagregimenaloneinpatientswithinermediatetohighriskmyelodysplasticsyndrome AT zhaochunshan comparisonofclinicalefficacybetweendecitabinecombinedwithhalftheamountofcagregimenwithcagregimenaloneinpatientswithinermediatetohighriskmyelodysplasticsyndrome AT wangwei comparisonofclinicalefficacybetweendecitabinecombinedwithhalftheamountofcagregimenwithcagregimenaloneinpatientswithinermediatetohighriskmyelodysplasticsyndrome AT yutingting comparisonofclinicalefficacybetweendecitabinecombinedwithhalftheamountofcagregimenwithcagregimenaloneinpatientswithinermediatetohighriskmyelodysplasticsyndrome |